HK Stock Market Move | METIS TECHBIO-P (07666) rose over 8%, achieving five consecutive days of gains. The AI pharmaceutical multinational cooperation project is accelerating to fruition, and the company is expected to be among the first to benefit from the industry's evolution.

METIS TECHBIO-P (07666) surged over 8% in early trading, marking five consecutive days of rises. As of the time of publication, it has increased by 5.39%, trading at HK$13.3, with a transaction volume of HK$17,299,500. On the news front, collaboration in the AI pharmaceutical sector has continued to heat up this year, with multinational cooperative projects accelerating implementation. Currently, renowned global pharmaceutical companies such as AstraZeneca, Pfizer, Johnson & Johnson, and Novartis have all established deep collaborations with domestic AI pharmaceutical companies, enhancing the international competitiveness of China's AI drug development technology. Notably, the world's "first AI drug delivery stock," METIS TECHBIO-P, has independently developed its AI nano-delivery platform, NanoForge, which integrates a diverse library of over ten million self-generated lipid structures and has achieved precise targeting of eight key organs and tissues, including the liver, lungs, heart, and muscles. Orient stated that as global regulations shift, the large-scale application of AI in pharmaceuticals is rapidly taking shape, evolving from early research tools into an end-to-end system covering the entire research and development chain, which is expected to disrupt the lengthy, costly, and high-failure-rate nature of innovative drug developmentoften referred to as the "inverse Moore's Law." The firm believes that overseas multinational corporations and tech giants are fully embracing AI, while domestic AI pharmaceutical companies are beginning to stand out, with companies in the related industrial chain, such as METIS TECHBIO-P, expected to benefit.